PPAR-γ Modulators as Current and Potential Cancer Treatments
Worldwide, cancer has become one of the leading causes of mortality. Peroxisome Proliferator-Activated Receptors (PPARs) is a family of critical sensors of lipids as well as regulators of diverse metabolic pathways. They are also equipped with the capability to promote eNOS activation, regulate immu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.737776/full |
id |
doaj-ae407acecca842979800dbbf3a82fb1a |
---|---|
record_format |
Article |
spelling |
doaj-ae407acecca842979800dbbf3a82fb1a2021-09-23T05:47:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.737776737776PPAR-γ Modulators as Current and Potential Cancer TreatmentsTiange Chi0Tiange Chi1Mina Wang2Mina Wang3Xu Wang4Ke Yang5Feiyu Xie6Feiyu Xie7Zehuan Liao8Zehuan Liao9Peng Wei10School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaFirst Clinical Medical School, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Acupuncture and Moxibustion, Beijing Key Laboratory of Acupuncture Neuromodulation, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaOncology Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaSchool of Biological Sciences, Nanyang Technological University, Singapore, SingaporeDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, SwedenSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaWorldwide, cancer has become one of the leading causes of mortality. Peroxisome Proliferator-Activated Receptors (PPARs) is a family of critical sensors of lipids as well as regulators of diverse metabolic pathways. They are also equipped with the capability to promote eNOS activation, regulate immunity and inflammation response. Aside from the established properties, emerging discoveries are also made in PPAR’s functions in the cancer field. All considerations are given, there exists great potential in PPAR modulators which may hold in the management of cancers. In particular, PPAR-γ, the most expressed subtype in adipose tissues with two isoforms of different tissue distribution, has been proven to be able to inhibit cell proliferation, induce cell cycle termination and apoptosis of multiple cancer cells, promote intercellular adhesion, and cripple the inflamed state of tumor microenvironment, both on transcriptional and protein level. However, despite the multi-functionalities, the safety of PPAR-γ modulators is still of clinical concern in terms of dosage, drug interactions, cancer types and stages, etc. This review aims to consolidate the functions of PPAR-γ, the current and potential applications of PPAR-γ modulators, and the challenges in applying PPAR-γ modulators to cancer treatment, in both laboratory and clinical settings. We sincerely hope to provide a comprehensive perspective on the prospect of PPAR-γ applicability in the field of cancer treatment.https://www.frontiersin.org/articles/10.3389/fonc.2021.737776/fullPPAR-γPPAR-γ modulatorsPPAR-γ agonistsPPAR-γ antagonistscancer treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tiange Chi Tiange Chi Mina Wang Mina Wang Xu Wang Ke Yang Feiyu Xie Feiyu Xie Zehuan Liao Zehuan Liao Peng Wei |
spellingShingle |
Tiange Chi Tiange Chi Mina Wang Mina Wang Xu Wang Ke Yang Feiyu Xie Feiyu Xie Zehuan Liao Zehuan Liao Peng Wei PPAR-γ Modulators as Current and Potential Cancer Treatments Frontiers in Oncology PPAR-γ PPAR-γ modulators PPAR-γ agonists PPAR-γ antagonists cancer treatment |
author_facet |
Tiange Chi Tiange Chi Mina Wang Mina Wang Xu Wang Ke Yang Feiyu Xie Feiyu Xie Zehuan Liao Zehuan Liao Peng Wei |
author_sort |
Tiange Chi |
title |
PPAR-γ Modulators as Current and Potential Cancer Treatments |
title_short |
PPAR-γ Modulators as Current and Potential Cancer Treatments |
title_full |
PPAR-γ Modulators as Current and Potential Cancer Treatments |
title_fullStr |
PPAR-γ Modulators as Current and Potential Cancer Treatments |
title_full_unstemmed |
PPAR-γ Modulators as Current and Potential Cancer Treatments |
title_sort |
ppar-γ modulators as current and potential cancer treatments |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
Worldwide, cancer has become one of the leading causes of mortality. Peroxisome Proliferator-Activated Receptors (PPARs) is a family of critical sensors of lipids as well as regulators of diverse metabolic pathways. They are also equipped with the capability to promote eNOS activation, regulate immunity and inflammation response. Aside from the established properties, emerging discoveries are also made in PPAR’s functions in the cancer field. All considerations are given, there exists great potential in PPAR modulators which may hold in the management of cancers. In particular, PPAR-γ, the most expressed subtype in adipose tissues with two isoforms of different tissue distribution, has been proven to be able to inhibit cell proliferation, induce cell cycle termination and apoptosis of multiple cancer cells, promote intercellular adhesion, and cripple the inflamed state of tumor microenvironment, both on transcriptional and protein level. However, despite the multi-functionalities, the safety of PPAR-γ modulators is still of clinical concern in terms of dosage, drug interactions, cancer types and stages, etc. This review aims to consolidate the functions of PPAR-γ, the current and potential applications of PPAR-γ modulators, and the challenges in applying PPAR-γ modulators to cancer treatment, in both laboratory and clinical settings. We sincerely hope to provide a comprehensive perspective on the prospect of PPAR-γ applicability in the field of cancer treatment. |
topic |
PPAR-γ PPAR-γ modulators PPAR-γ agonists PPAR-γ antagonists cancer treatment |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.737776/full |
work_keys_str_mv |
AT tiangechi ppargmodulatorsascurrentandpotentialcancertreatments AT tiangechi ppargmodulatorsascurrentandpotentialcancertreatments AT minawang ppargmodulatorsascurrentandpotentialcancertreatments AT minawang ppargmodulatorsascurrentandpotentialcancertreatments AT xuwang ppargmodulatorsascurrentandpotentialcancertreatments AT keyang ppargmodulatorsascurrentandpotentialcancertreatments AT feiyuxie ppargmodulatorsascurrentandpotentialcancertreatments AT feiyuxie ppargmodulatorsascurrentandpotentialcancertreatments AT zehuanliao ppargmodulatorsascurrentandpotentialcancertreatments AT zehuanliao ppargmodulatorsascurrentandpotentialcancertreatments AT pengwei ppargmodulatorsascurrentandpotentialcancertreatments |
_version_ |
1717370640851271680 |